CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (DEFICIT) - USD ($) $ in Thousands	Total	Common Stock Issued	Additional Paid-in Capital	Treasury Stock	Accumulated Deficit
Balance beginning of period (in shares) at Dec. 31, 2022		113,705,447
Balance, beginning of period at Dec. 31, 2022	$ (17,988)	$ 114	$ 173,804	$ 0	$ (191,906)
Treasury stock, beginning balance (in shares) at Dec. 31, 2022				0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share-based compensation expense	4,345		4,345
Issuance of restricted stock (in shares)		1,439,676		(57,770)
Issuance of restricted stock	0	$ 1	(179)	$ 178
Restricted stock shares canceled/forfeited	0		179	$ (179)
Restricted stock canceled/forfeited (in shares)				58,104
Employee stock purchase plan (in shares)		235,419
Employee stock purchase plan	680		680
Net income (loss)	(4,983)				(4,983)
Balance end of period (in shares) at Mar. 31, 2023		115,380,542
Balance, end of period at Mar. 31, 2023	$ (17,946)	$ 115	178,829	$ (1)	(196,889)
Treasury stock, ending balance (in shares) at Mar. 31, 2023				334
Balance beginning of period (in shares) at Dec. 31, 2023	146,227,639	146,227,639
Balance, beginning of period at Dec. 31, 2023	$ 142,717	$ 146	276,249	$ 0	(133,678)
Treasury stock, beginning balance (in shares) at Dec. 31, 2023				0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share-based compensation expense	4,340		4,340
Exercise of stock options (in shares)		109,920
Exercise of stock options	766		766
Employee stock purchase plan (in shares)		121,783
Employee stock purchase plan	797		797
Issuance of restricted stock, net (in shares)		1,069,254
Issuance of restricted stock, net	(2,150)	$ 2	(2,152)
Net income (loss)	$ 9,261				9,261
Balance end of period (in shares) at Mar. 31, 2024	147,528,596	147,528,596
Balance, end of period at Mar. 31, 2024	$ 155,731	$ 148	$ 280,000	$ 0	$ (124,417)
Treasury stock, ending balance (in shares) at Mar. 31, 2024				0